Pacific Biosciences of California PACB Settlement charges

Segments

By segment

See full

Reportable Segment$15.4M—

Other financials

Income statement

See full

Revenue$37.2M+0.1%

Gross profit$12.8M+1,037%

Operating income-$8.4M+98.1%

Net income-$8.3M+98.1%

EPS (diluted)-$0.03+97.9%

Balance sheet

See full

Cash & equivalents$57.9M-4.7%

Total debt$59.3M+12.1%

Total equity$2.4M-97.4%

Total assets$782.4M-9.1%

Cash flow

See full

Operating cash flow-$44.7M-1.4%

CapEx$3.0M+119%

Free cash flow-$47.7M-5.0%

Valuation

See full

Market cap$496.96M+30.4%

Enterprise value$498.38M+33.5%

P/S3.1×+0.6×

Profitability

See full

Gross margin37.5%+21.3pp

Operating margin-83.3%-38.2pp

Net margin-80.3%-36.1pp

FCF margin-72.6%-20.0pp

Returns & leverage

See full

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept pacb:SettlementCharges.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's settlement charges.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacific Biosciences of California's settlement charges?: Pacific Biosciences of California (PACB) reported settlement charges of $15.4M in Q1 2026.